Ozyigit G, Hurmuz P, Yuce D, Akyol F. Prognostic significance of castrate testosterone levels for patients with intermediate and high risk prostate cancer. World J Clin Oncol 2019; 10(8): 283-292 [PMID: 31528544 DOI: 10.5306/wjco.v10.i8.283]
Corresponding Author of This Article
Gokhan Ozyigit, MD, Full Professor, Department of Radiation Oncology, Hacettepe University Faculty of Medicine, Ankara 06100, Turkey. gozyigit@hacettepe.edu.tr
Research Domain of This Article
Oncology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Oncol. Aug 24, 2019; 10(8): 283-292 Published online Aug 24, 2019. doi: 10.5306/wjco.v10.i8.283
Prognostic significance of castrate testosterone levels for patients with intermediate and high risk prostate cancer
Gokhan Ozyigit, Pervin Hurmuz, Deniz Yuce, Fadil Akyol
Gokhan Ozyigit, Pervin Hurmuz, Fadil Akyol, Department of Radiation Oncology, Hacettepe University Faculty of Medicine, Ankara 06100, Turkey M.D.
Deniz Yuce, Department of Preventive Oncology, Hacettepe University Faculty of Medicine, Ankara 06100, Turkey
Author contributions: Ozyigit G and Akyol F designed research; Ozyigit G, Akyol F and Hurmuz P performed research; Yuce D and Hurmuz P analyzed data; Hurmuz P, Ozyigit G, Yuce D and Akyol F wrote the paper.
Institutional review board statement: The study was reviewed and approved by the Hacettepe University Faculty of Medicine ethics Committee.
Informed consent statement: Provided; nevertheless, patient’s initials or characteristics are not exposed.
Conflict-of-interest statement: The authors declare no potential conflict of interest in this paper.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Gokhan Ozyigit, MD, Full Professor, Department of Radiation Oncology, Hacettepe University Faculty of Medicine, Ankara 06100, Turkey. gozyigit@hacettepe.edu.tr
Telephone: +90-312-3052019
Received: February 26, 2019 Peer-review started: February 27, 2019 First decision: April 11, 2019 Revised: May 5, 2019 Accepted: July 30, 2019 Article in press: July 30, 2019 Published online: August 24, 2019
Core Tip
Core tip: Castrate testosterone level of less than 20 ng/dL achieved after primary radiotherapy plus androgen deprivation treatment for non-metastatic prostate cancer is associated with better biochemical relapse free survival. Testosterone level of < 50 ng/dL has been used to define castrate level after surgery or after androgen deprivation treatment in metastatic prostate cancer (PC). In this study, we evaluated the effect of two different castrate testosterone levels, < 50 and < 20 ng/dL, on biochemical relapse free survival in patients with non-metastatic intermediate and high risk PC receiving definitive modern radiotherapy and androgen deprivation treatment. With a median follow up of 125 mo we found that castrate testosterone level of less than 20 ng/dL achieved after primary radiotherapy plus androgen deprivation treatment was found to be associated with better biochemical relapse free survival.
